An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Fiche publication

Date publication

mars 2021

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr THIERY-VUILLEMIN Antoine

Tous les auteurs :
Thiery-Vuillemin A, Fizazi K, Sartor O, Oudard S, Bury D, Thangavelu K, Ozatilgan A, Poole EM, Eisenberger M, de Bono J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33740734

Résumé

Men with metastatic castration-resistant prostate cancer (mCRPC) are living longer, therefore optimizing health-related quality of life (HRQL), as well as survival outcomes, is important for optimal patient care. The aim of this study was to assess the HRQL in patients with mCRPC receiving docetaxel or cabazitaxel.